Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Estonia
Estonia- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 968
- countries
- 28
- conditions
- 2 103
3 968 trials recruiting28 European countries2 103 conditions coveredUpdated today
192 trials match your criteria
Recruiting
Renal disorder
RecruitingBI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases
Investigational
BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases
Investigational
- Disease:Renal disorder
- Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
Countries:Estonia
Estonia- Participants:0–17 years · 18–64 years · 65+ years
- Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
Recruiting
Primary progressive multiple sclerosis
RecruitingOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:–
Countries:Estonia
Estonia- Participants:18–64 years
Recruiting
Psoriatic arthropathy
RecruitingLong-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
Investigational
Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
Investigational
- Disease:Psoriatic arthropathy
- Substances:Zasocitinib
Countries:Estonia
Estonia- Participants:18–64 years · 65+ years
- Substances:Zasocitinib
Recruiting
Colorectal cancer metastatic
RecruitingStudy of Sotorasib, Panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.
Registered drugNo placebo
Study of Sotorasib, Panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.
Registered drugNo placebo
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabCalcium Folinate+4
Countries:Estonia
Estonia- Participants:18–64 years
- Substances:Bevacizumab
Recruiting
A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Registered drug
A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Registered drug
- Disease:Chronic inflammatory demyelinating polyradiculoneuropathy
- Substances:EmpasiprubartHuman Normal Immunoglobulin (Iv)
Countries:Estonia
Estonia- Participants:18–64 years · 65+ years
- Substances:Empasiprubart
Recruiting
Psoriatic arthropathy
RecruitingStudy of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines
Registered drug
Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines
Registered drug
- Disease:Psoriatic arthropathy
- Substances:ApremilastZasocitinib
Countries:Estonia
Estonia- Participants:18–64 years · 65+ years
- Substances:Apremilast
Recruiting
Acute myocardial infarction
RecruitingStudy on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History
Investigational
Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History
Investigational
- Disease:Acute myocardial infarction
- Substances:Selatogrel
Countries:Estonia
Estonia- Participants:18–64 years · 65+ years
- Substances:Selatogrel
Recruiting
Crohn's disease
RecruitingStudy on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease
Investigational
Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease
Investigational
- Disease:Crohn's disease
- Substances:Morf-057
Countries:Estonia
Estonia- Participants:18–64 years · 65+ years
- Substances:Morf-057
Recruiting
Neoplasm malignant
RecruitingStudy on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors
Registered drugNo placebo
Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors
Registered drugNo placebo
- Disease:Neoplasm malignant
- Substances:FavezelimabLenvatinib+2
Countries:Estonia
Estonia- Participants:18–64 years · 65+ years
- Substances:Favezelimab
Recruiting
Arteriosclerosis
RecruitingStudy on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis
Investigational
Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis
Investigational
- Disease:Arteriosclerosis
- Substances:Clazakizumab
Countries:Estonia
Estonia- Participants:18–64 years · 65+ years
- Substances:Clazakizumab
Recruiting
Atrial fibrillation
RecruitingStudy on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation
Investigational
Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation
Investigational
- Disease:Atrial fibrillation
- Substances:Abelacimab
Countries:Estonia
Estonia- Participants:65+ years
- Substances:Abelacimab